Referral Barriers in Advanced cSCC Care: What Dermatology Clinics Should Know

Clinically Reviewed by Dr. C. Alahakoon | Published on 24 July 2026

Referral Barriers in Advanced cSCC Care: What Dermatology Clinics Should Know - Glowgau Clinical Analysis

Referral Barriers in Advanced cSCC Care: What Dermatology Clinics Should Know

Advanced cutaneous squamous cell carcinoma (cSCC) care faces persistent referral barriers between dermatologists and oncologists, creating delays that can affect treatment outcomes.

Short answer

Referral barriers between dermatology and oncology persist in advanced cSCC care. A 2026 study found that integrated multidisciplinary care reduces time to treatment, but coordination gaps remain. Dermatology clinics should be aware of these barriers and consider how streamlined referral pathways can improve client outcomes.

Why this matters for aesthetic clinics

While cSCC is a skin cancer topic rather than a cosmetic concern, dermatology clinics that offer both medical and aesthetic services are directly affected. Clients who experience referral delays may lose trust in their clinic's care coordination. A 2026 study in the Journal of the American Academy of Dermatology found that integrated multidisciplinary care significantly reduced time to treatment for advanced cSCC [1].

However, a critique published alongside the study noted that time itself is a substantial confounder — patients who reach multidisciplinary care faster may already have less advanced disease [2]. The original authors responded that even after adjustment, the multidisciplinary approach showed benefit [3].

What clinics should consider

  1. Referral pathway clarity. Clients referred between dermatology and oncology should have a clear, documented pathway. Ambiguity about who is responsible for the next step creates delays.

  2. Communication tools. Structured intake and referral communication reduces information loss between specialists. Clinics that use structured digital intake can capture the right information before the referral is made.

  3. European guideline update. A 2026 European consensus-based interdisciplinary guideline for invasive cSCC treatment was published, providing updated standards for care coordination [4].

  4. Clinical caution. The "Evolving Paradigms" event referenced in the original intel could not be independently verified as a specific named conference. The underlying clinical content — referral barriers in advanced cSCC — is well-supported by peer-reviewed literature.

Practical takeaway

Dermatology clinics should review their referral pathways for advanced skin cancer cases and ensure structured communication between specialists.

How Glowgau supports this workflow

Glowgau helps clinics structure their intake and communication pathways — capturing client concerns and medical context in a clinic-controlled, HIPAA-aware system. This supports clearer handoffs between specialists. Try Glowgau at https://glowgau.com, or contact contact@glowgau.com with questions.

Read more

Verification and publication

Verified and published by Dr. C. Alahakoon, Clinician and Clinical Data Scientist. LinkedIn: www.linkedin.com/in/chandimal-alahakoon-ln

References

  1. Ran NA, et al. "Integrated Multidisciplinary Care Reduces Time to Treatment in Patients With Advanced Cutaneous Squamous Cell Carcinoma." J Am Acad Dermatol. 2026 Aug. PMID: 41935787.
  2. Wang T, et al. "Time as a Substantial Confounder in Evaluating Integrated Multidisciplinary Care for Advanced cSCC." J Am Acad Dermatol. 2026 Jun. PMID: 42264380.
  3. Ran NA, et al. "Response to Wang et al." J Am Acad Dermatol. 2026 Jun. PMID: 42264381.
  4. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026. Eur J Cancer. 2026 Jul. PMID: 42263355.